Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
  • CHIMERIC ENZYMES WITH IMPROVED CELLULASE ACTIVITIES
    Publication number: 20140017734
    Abstract: Nucleic acid molecules encoding chimeric cellulase polypeptides that exhibit improved cellulase activities are disclosed herein. The chimeric cellulase polypeptides encoded by these nucleic acids and methods to produce the cellulases are also described, along with methods of using chimeric cellulases for the conversion of cellulose to sugars such as glucose.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 16, 2014
    Inventors: Qi XU, John O. BAKER, Michael E. HIMMEL
  • Fusion Molecules of Rationally-Designed DNA-Binding Proteins and Effector Domains
    Publication number: 20140010797
    Abstract: Targeted transcriptional effectors (transcription activators and transcription repressors) derived from meganucleases are described. Also described are nucleic acids encoding same, and methods of using same to regulate gene expression. The targeted transcriptional effectors can comprise (i) a meganuclease DNA-binding domain lacking endonuclease cleavage activity that binds to a target recognition site; and (ii) a transcription effector domain.
    Type: Application
    Filed: September 19, 2012
    Publication date: January 9, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Derek JANTZ, Michael G. NICHOLSON, James Jefferson SMITH
  • Biotin Derivatives
    Publication number: 20140011255
    Abstract: Biotin derivatives, methods of using the biotin derivatives and kits comprising the biotin derivatives.
    Type: Application
    Filed: October 28, 2011
    Publication date: January 9, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Lai-Qiang Ying, Bruce Branchauo, Yu-Zhong Zhang, Stephen Yue
  • ANTIBODIES FOR TUMOR GANGLIOSIDES
    Publication number: 20140010829
    Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.
    Type: Application
    Filed: November 15, 2011
    Publication date: January 9, 2014
    Applicants: The Gov't of the United States, as Represented by, The Secretary of Health and Human Services, DUKE UNIVERSITY
    Inventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
  • Engineered cleavage half-domains
    Patent number: 8623618
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: January 7, 2014
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • SITE SPECIFICALLY INCORPORATED INITIATOR FOR GROWTH OF POLYMERS FROM PROTEINS
    Publication number: 20140004591
    Abstract: The present invention is directed towards a protein-polymer composition having a protein with a site-specifically incorporated unnatural amino acid initiator and a covalently attached polymer.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 2, 2014
    Applicant: FRANKLIN AND MARSHALL COLLEGE
    Inventors: Ryan A. Mehl, Krzysztof Matyjaszewski, Saadyah Averick
  • Dendrimer-Based Excipients for the Attenuation of Protein Aggregation
    Publication number: 20140004592
    Abstract: One aspect of the invention is a salt comprising guanidinium groups, as shown in formula I. Another aspect of the invention is a salt comprising guanidinium groups, as shown in formula II. Another aspect of the invention is a salt comprising guanidinium groups, as shown in formula III. Another aspect of the invention is a salt comprising guanidinium groups, as shown in formula IV. Yet another aspect of the invention is a salt comprising guanidinium groups, as shown in formula I, II, III, and IV further comprising independently for each occurrence citrate, phosphate, or sulfate anion. Also disclosed are compositions comprising a protein and a salt comprising guanidinium groups, as shown in formula I, II, III, and IV. Also provided are methods of increasing shelf life of an aqueous solution of a protein and decreasing the amount of protein aggregation in an aqueous solution of a protein.
    Type: Application
    Filed: November 11, 2011
    Publication date: January 2, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Bernhardt L. Trout, II, Diwakar Shukla, Curtiss P. Schneider
  • PCSK9 VACCINE
    Publication number: 20140004142
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide containing a phosphorylation site (with or without phosphorylation of the site) linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositions thereof and their use in medicine.
    Type: Application
    Filed: February 28, 2012
    Publication date: January 2, 2014
    Applicant: PFIZER INC.
    Inventors: Brian Robert Champion, James Downey Fraser, George Joseph Smith, Clare Lees
  • SASPASE-FLG2 COMPLEX, MODULATING AGENTS, AND USES
    Publication number: 20140005207
    Abstract: The present invention relates to the use of a compound, suitable for modulating the interaction between first and second partner proteins, or between homologues, mutants, or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2, as an active agent for treating and/or preventing aesthetic defects in the skin, and/or in the appendages thereof, linked to an imbalance in the differentiation and/or proliferation of the cells of the epidermis.
    Type: Application
    Filed: December 5, 2011
    Publication date: January 2, 2014
    Applicant: L'OREAL
    Inventors: Dominique Bernard, Agnes Thomas-Collignon, Roger Rozot, Benoit Muller
  • Class I Anti-CEA Antibodies and Uses Thereof
    Publication number: 20130344071
    Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 26, 2013
    Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
  • Recombinant Colwellia Psychrerythraea Alkaline Phosphatase and Uses Thereof
    Publication number: 20130344493
    Abstract: A heat labile alkaline phosphatase enzyme and methods of using the same and kits including the same are disclosed. Specifically, a nucleotide sequence of, peptide sequence of, methods of using, and kits comprising, a heat labile alkaline phosphatase isolated from Colwellia psychrerythraea are provided. Methods of over-expression and purification of the recombinant alkaline phosphatase and mutants thereof are also disclosed. Methods of over-expressing and purifying commercially useful quantities of active recombinant heat labile alkaline phosphatase fusion enzymes from C. psychrerythraea, wherein the fusion enzymes comprise one or more heterologous leader sequences are disclosed. The disclosed C. psychrerythraea heat labile alkaline phosphatase has properties similar to shrimp alkaline phosphatase and can be substituted for shrimp alkaline phosphatase in assays involving the same.
    Type: Application
    Filed: June 13, 2013
    Publication date: December 26, 2013
    Applicant: Affymetrix, Inc.
    Inventors: Jeannine C. Muller-Greven, Marc A. Post, Christopher J. Kubu
  • GNTIII EXPRESSION IN PLANTS
    Publication number: 20130347146
    Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 26, 2013
    Applicant: Stichting Dienst Landbouwkundig Onderzoek
    Inventors: Hendrikus Antonius Cornelis Bakker, Dionisius Elisabeth Antonius Florack, Hendrik Jan Bosch
  • ANTIBODY CONJUGATES AGAINST VARIANT NFKBIB AND USES THEREOF
    Publication number: 20130344076
    Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.
    Type: Application
    Filed: March 26, 2013
    Publication date: December 26, 2013
    Applicant: Viventia Bio Inc.
    Inventors: Francina C. CHAHAL, Jeannick CIZEAU
  • Glycopegylated Factor IX
    Publication number: 20130344050
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: May 20, 2013
    Publication date: December 26, 2013
    Applicant: Novo Nordisk A/S
    Inventor: Novo Nordisk A/S
  • Compostion of matter for treating or preventing various types of cancer and neoplastic diseases in a mammal
    Publication number: 20130344051
    Abstract: A composition of matter can reduce size of cancerous tumors in mammals. The composition of matter comprises Bromelain infused with vitamin C creating a protein enzyme complex which can be administered in an effective amount to reduce the size of cancerous tumors in mammals.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: GARFIELD MEDICAL GROUP
    Inventors: BENEDICT SCHUE LIAO, AUSTIN LEWIS LIAO, JUDY FU-CHUAN LI-LIAO, BURTON ARTHUR LI-LIAO, JUSTIN LIAO, EDWARD REGEAN LIAO, ROBERT LIAO, SUSAN JOAN LIAO-NIENG, SU-LIEN LIAO-CHEN, LUDWIG SCHUE-LIAO, LILY LIAO, SUSAN SU-HSIN LIAO-TUNG, ALEX BISMARK LIAO, STANLEY LEO, NELSON BENSON LEO
  • PEG-MODIFIED ARGININE/LYSINE OXIDOREDUCTASE
    Publication number: 20130344052
    Abstract: The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol, a production method thereof, and methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.
    Type: Application
    Filed: September 9, 2013
    Publication date: December 26, 2013
    Inventors: Christian J. Hofmann, Michael Lindemann
  • ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF
    Publication number: 20130344067
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
  • FUSION PROTEIN FOR SECRETORY PROTEIN EXPRESSION
    Publication number: 20130344099
    Abstract: There is provided a fusion protein suitable for secretion of more than one polypeptide(s) of interest (POI) comprising a signal peptide, a POI, a passenger domain comprising a beta stem domain from an autotransporter protein, and a translocator domain from an autotransporter protein, wherein the beta stem-forming sequence of the passenger domain is essentially intact and the POI(s) is/are fused to the beta stem domain.
    Type: Application
    Filed: September 28, 2011
    Publication date: December 26, 2013
    Applicant: ABERA BIOSCIENCE AB
    Inventors: Joen Luirink, Wouter S. P. Jong
  • Xylanases, Nucleic Acids Encoding Them and Methods for Making and Using Them
    Publication number: 20130337507
    Abstract: The invention relates to xylanases and to polynucleotides encoding the xylanases. In addition, methods of designing new xylanases and methods of use thereof are also provided. The xylanases have increased activity and stability at increased pH and temperature.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Applicants: Verenium Corporation, BP Corporation North America Inc.
    Inventors: Brian Steer, Walter Callen, Shaun Healey, Geoff Hazlewood, Di Wu, David Blum, Alireza Esteghlalian
  • PEPTIDES AND USES
    Publication number: 20130336947
    Abstract: Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in mutant genes and may have applications in gene therapy. The zinc finger peptides may have nucleic acid recognition sequences according to SEQ ID NO: 101. Also disclosed are methods for constructing poly-zinc finger peptides having arrays of at least 8 zinc finger domains, along with zinc finger frameworks that may be useful for selecting zinc finger peptides from libraries.
    Type: Application
    Filed: October 17, 2011
    Publication date: December 19, 2013
    Applicant: FUNDACIÓ PRIVADA CENTRE DE REGULACIÓ GENÓMICA
    Inventors: Mark Isalan, Mireia Garriga-Canut
  • Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation
    Publication number: 20130337534
    Abstract: The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.
    Type: Application
    Filed: August 5, 2013
    Publication date: December 19, 2013
    Applicant: Oligasis, LLC
    Inventor: Stephen A. Charles
  • COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS
    Publication number: 20130337537
    Abstract: The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention.
    Type: Application
    Filed: March 2, 2012
    Publication date: December 19, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
  • COMPOSITIONS AND METHODS FOR MODULATING AMPA RECEPTOR-MEDIATED EXCITOTOXICITY
    Publication number: 20130336951
    Abstract: The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are also disclosed.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 19, 2013
    Applicant: Centre For Addiction And Mental Health
    Inventor: Fang LIU
  • Labeling Reagents and Methods of Their Use
    Publication number: 20130337536
    Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 19, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Evan Antoulinakis, Kyle Gee, Aleksey Rukavishnikov
  • Fusion Polypeptides Comprising an Active Protein Linked to a Mucin-Domain Polypeptide
    Publication number: 20130338067
    Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 19, 2013
    Inventors: JUAN ALVAREZ, JEAN CHAMOUN, HEATHER C. LOSEY
  • Control of Cyanate in Aqueous Urea Solutions by Non-1,2-Ethylene Diamine Like Compounds for the Protection of Protein/Peptide Carbamylation
    Publication number: 20130337535
    Abstract: Embodiments of the present invention generally relate to processing of peptides in urea solutions and substantial prevention of carbamylation of the peptide.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 19, 2013
    Applicant: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    Inventors: Philip A. Ropp, Christie Lynn Williams, Michael Murray, Miao Fang Lin
  • FUSION PROTEINS AND METHODS FOR TREATING HIV INFECTION AND AIDS RELATED SYMPTOMS
    Publication number: 20130336946
    Abstract: The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection.
    Type: Application
    Filed: February 1, 2011
    Publication date: December 19, 2013
    Applicant: TIANJIN XIJI BIOTECHNOLOGY CO., LTD.
    Inventors: Pingfan Rao, Shutao Liu
  • Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt
    Publication number: 20130337533
    Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.
    Type: Application
    Filed: June 28, 2013
    Publication date: December 19, 2013
    Inventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
  • Sp35 Antibodies and Uses Thereof
    Publication number: 20130336991
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, R. Blake PEPINSKY, Zhaohui SHAO, Christilyn GRAFF
  • MUTANT PROTEINASE WITH REDUCED SELF-CLEAVAGE ACTIVITY AND METHOD OF PURIFICATION
    Publication number: 20130337503
    Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 19, 2013
    Applicant: YALE UNIVERSITY
    Inventors: Jennifer A. DOUDNA, Louise J. Lucast, Robert T. Batey
  • THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY
    Publication number: 20130337532
    Abstract: The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. For example, the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 19, 2013
    Applicant: CSL BEHRING GMBH
    Inventors: Thomas Weimer, Hubert Metzner, Stefan Schulte, Wiegand Lang, Wilfried Wormsbacher
  • GASTRO-RESISTANT ENZYME PHARMACEUTICAL COMPOSITIONS
    Publication number: 20130337062
    Abstract: The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes.
    Type: Application
    Filed: May 1, 2013
    Publication date: December 19, 2013
    Applicant: Aptalis Pharma Canada Inc.
    Inventor: Aptalis Pharma Canada Inc.
  • METHOD FOR INCREASING THE EFFICIENCY OF DOUBLE-STRAND BREAK-INDUCED MUTAGENESIS
    Publication number: 20130337454
    Abstract: The present invention relates to a method for increasing double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. More specifically, the present invention concerns a method for increasing double-strand break-induced mutagenesis at a genomic locus of interest, leading to a loss of genetic information and preventing any scarless re-ligation of said genomic locus of interest by NHEJ. The present invention also relates to engineered endonucleases, chimeric or not, vectors, compositions and kits used to implement this method.
    Type: Application
    Filed: October 27, 2011
    Publication date: December 19, 2013
    Inventors: Philippe Duchateau, Alexandre Juillerat, George H. Silva, Jean-Charles Epinat
  • ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF
    Publication number: 20130336955
    Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.
    Type: Application
    Filed: January 9, 2012
    Publication date: December 19, 2013
    Applicant: VALIANT BIOPHARMA SDN BHD
    Inventors: Muhammad Sagaf Abu Bakar, Ag., Eng Huan Ung
  • Assay for colon and other cancers in humans
    Publication number: 20130330742
    Abstract: The present invention is concerned with a novel antigen associated with human tumors, including carcinomas of the colon, pancreas, and lung, as well as novel monoclonal antibodies which binds strongly to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. The novel antigen disclosed is a 60,000 Dalton glycoprotein found on the cell surface of human tumor cells.
    Type: Application
    Filed: December 1, 2010
    Publication date: December 12, 2013
    Applicant: EDP Biotech Corporation
    Inventor: Tommye Jordan
  • EYE DROP COMPOSITION FOR PREVENTION AND TREATMENT OF OPHTHALMIC DISEASES CONTAINING FUSION PROTEIN OF FK506 BINDING PROTEIN
    Publication number: 20130330368
    Abstract: Disclosed is a treatment for ophthalmic diseases, more specifically, a pharmaceutical composition for treating ophthalmic diseases including a fusion protein of FK506 binding protein capable of penetrating into the ocular tissue as an active ingredient.
    Type: Application
    Filed: April 6, 2011
    Publication date: December 12, 2013
    Applicant: INDUSTRY ACADEIC COOPERATION FOUNDATION, HALLYM UNIVERSITY
    Inventors: Soo Young Choi, Dae Won Kim, Sung Ho Lee, Jinseu Park, Won Sik Eum
  • COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS
    Publication number: 20130330343
    Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
    Type: Application
    Filed: December 13, 2012
    Publication date: December 12, 2013
    Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
  • CRYSTAL STRUCTURE AND PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE
    Publication number: 20130330358
    Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 12, 2013
    Inventors: Jae Jung, Hye-Ra Lee, Myung Hee Kim, Tae-Kwang Oh, Jung-Won Hwang
  • POLYPEPTIDES HAVING GLUCOAMYLASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20130333072
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 30, 2010
    Publication date: December 12, 2013
    Applicants: Novozymes North America, Inc., Novozymes A/S
    Inventors: Sara Landvik, Keiichi Ayabe, Guillermo Coward-Kelly
  • TEMPERATURE-STABLE BETA-PYRANOSIDASE
    Publication number: 20130330784
    Abstract: The invention relates to temperature-stable polypeptides with ?-pyranosidase activity. The polypeptide substrates include ?-glucopyranosides und ?-xylopyranosides. Said polypeptides can be expressed alone or as fusion proteins for example in yeast or bacteria and subsequently purified. The polypeptides according to said invention can be used alone or in a mixture with other enzymes for the degradation of plant raw materials, among others for the enzymatic degradation of biomass containing lignocellulose, in particular hemicellulose and the hemicellulose component xylan. Said enzymes are suitable for use in textile processing, as an additive of detergents, or in the food or feed industry.
    Type: Application
    Filed: October 26, 2011
    Publication date: December 12, 2013
    Applicant: CLARIANT PRODUKTE (DEUTSCHLAND) GMBH
    Inventors: Christoph Reisinger, Farah Qoura, Barbara Klippel, Garabed Antranikian
  • METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
    Publication number: 20130330414
    Abstract: This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 12, 2013
    Applicant: UTI Limited Partnership
    Inventor: Pedro Santamaria
  • ANTI-IL-TIF ANTIBODIES
    Publication number: 20130330330
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Application
    Filed: July 30, 2013
    Publication date: December 12, 2013
    Applicant: ZYMOGENETICS, INC.
    Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Steven D. HUGHES, Yasmin A. CHANDRASEKHER
  • BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
    Publication number: 20130330335
    Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.
    Type: Application
    Filed: March 21, 2011
    Publication date: December 12, 2013
    Applicant: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan
  • METHOD FOR PRODUCTION OF RECOMBINANT HUMAN IDURONATE 2-SULFATASE
    Publication number: 20130330802
    Abstract: Disclosed is a method for production of recombinant human iduronate 2-sulfatase (rhI2S) in a large scale, with a high purity, and mannose 6-phosphate residues. The method comprises the steps of (a) culturing rhI2S-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to cation-exchange column chromatography, (d) to dye affinity column chromatography, (e) to anion-exchange column chromatography, and (f) to a column chromatography employing as solid phase a material having affinity for phosphate group, and (g) to gel filtration column chromatography, in the order.
    Type: Application
    Filed: January 23, 2012
    Publication date: December 12, 2013
    Applicant: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Kazutoshi Mihara, Atsuko Kawasaki, Kouta Ootsuki, Yuukichi Hatano, Shoichiro Kamei, Atsushi Sugimura
  • MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS
    Publication number: 20130324483
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: August 9, 2013
    Publication date: December 5, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
  • ENDOPLASMIC RETICULUM CALCIUM ATPASE KINETICS INDICATOR AND USE THEREOF
    Publication number: 20130323769
    Abstract: The present invention provides a fusion protein including sarco/endoplasmic reticulum calcium ATPase, a fluorescence donor for FRET, and a fluorescence acceptor, one of the fluorescence donor and the fluorescence acceptor being linked to the N-terminus side of the ATPase, the other of the fluorescence donor and the fluorescence acceptor being inserted between the above one of the fluorescence donor and the fluorescence acceptor and the ATPase or being inserted in an amino acid sequence of the ATPase, the amino acid sequence corresponding to (i) amino acids 1 through 6 in SERCA2a, (ii) amino acids 369 through 380 in the SERCA2a or (iii) amino acids 572 through 583 in the SERCA2a.
    Type: Application
    Filed: January 13, 2012
    Publication date: December 5, 2013
    Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, RIKEN
    Inventors: Katsuhiko Mikoshiba, Toru Matsu-Ura, Kanayo Satoh
  • PEPTIDES FOR THE SPECIFIC BINDING OF RNA TARGETS
    Publication number: 20130323813
    Abstract: A recombinant polypeptide is described including at least one PUF RNA-binding domain capable of specifically binding to a cytosine RNA base. The PUF RNA-binding domain of the polypeptide includes at least one RNA base-binding motif of the general formula X1X2X3X4X5X6X7X8X9X10X11 wherein X1 is selected from a defined group and wherein the RNA base-binding motif is operably capable of specifically binding to a cytosine RNA base.
    Type: Application
    Filed: November 24, 2011
    Publication date: December 5, 2013
    Applicant: THE UNIVERSITY OF WESTERN AUSTRALIA
    Inventors: Aleksandra Filipovska, Oliver Rackham
  • PEPTIDES THAT MODULATE COMPLEX SASPASE-FLG2
    Publication number: 20130324477
    Abstract: The invention relates to a peptide isolated from SASpase or FLG2, a fragment or homologue thereof, which can modify the three-dimensional shape of a complex formed by interaction between a first amino acide sequence from Filaggrin-2 and a second amino acid sequence from SASPase.
    Type: Application
    Filed: December 5, 2011
    Publication date: December 5, 2013
    Applicant: L'OREAL
    Inventors: Dominique Bernard, Agnes Thomas-Collignon
  • IN SITU RESTORATION OF APATITE-BASED CHROMATOGRAPHY RESINS
    Publication number: 20130323812
    Abstract: Methods and compositions are provided for treatment of an apatite-based resin from which retained solutes have been eluted by an elution buffer that contains an alkali metal salt with solutions of calcium ion, phosphate ion, and hydroxide separately from any sample loading and elution buffers. The treatment solutions restore the resin, reversing the deterioration that is caused by the alkali metal salt in the elution buffer.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 5, 2013
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: Larry J. Cummings, Jie He
  • BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
    Publication number: 20130323752
    Abstract: In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the Bcl-2 family of proteins. It is named BLID (Bcl2 family of proteins Like Interaction Domain). Use of BLID and its variants for modulating cellular activity is presented. BLID, its variants and or anti-BLID antibodies could be useful as a screening tool as well as for discovery of drugs that help fight pathological states like degenerative diseases, cerebral or cardiac ischemic hypoxic disorders, cancer and autoimmunity.
    Type: Application
    Filed: November 14, 2012
    Publication date: December 5, 2013
    Inventor: Carlos Witte-Hoffmann